APA (7th ed.) Citation

Mateos, M., & Goldschmidt, H. (2018). Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials. Hematological oncology, 36(2), . https://doi.org/10.1002/hon.2499

Chicago Style (17th ed.) Citation

Mateos, Maria-Victoria, and Hartmut Goldschmidt. "Carfilzomib in Relapsed or Refractory Multiple Myeloma Patients with Early or Late Relapse Following Prior Therapy: A Subgroup Analysis of the Randomized Phase 3 ASPIRE and ENDEAVOR Trials." Hematological Oncology 36, no. 2 (2018). https://doi.org/10.1002/hon.2499.

MLA (9th ed.) Citation

Mateos, Maria-Victoria, and Hartmut Goldschmidt. "Carfilzomib in Relapsed or Refractory Multiple Myeloma Patients with Early or Late Relapse Following Prior Therapy: A Subgroup Analysis of the Randomized Phase 3 ASPIRE and ENDEAVOR Trials." Hematological Oncology, vol. 36, no. 2, 2018, https://doi.org/10.1002/hon.2499.